Andre C. Schuh

17.2k total citations · 4 hit papers
181 papers, 7.8k citations indexed

About

Andre C. Schuh is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andre C. Schuh has authored 181 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Hematology, 54 papers in Genetics and 54 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andre C. Schuh's work include Acute Myeloid Leukemia Research (114 papers), Chronic Myeloid Leukemia Treatments (53 papers) and Acute Lymphoblastic Leukemia research (53 papers). Andre C. Schuh is often cited by papers focused on Acute Myeloid Leukemia Research (114 papers), Chronic Myeloid Leukemia Treatments (53 papers) and Acute Lymphoblastic Leukemia research (53 papers). Andre C. Schuh collaborates with scholars based in Canada, United States and Germany. Andre C. Schuh's co-authors include Fouad Shalaby, Janet Rossant, Martin L. Breitman, Xiang‐Fu Wu, Marina Gertsenstein, Terry P. Yamaguchi, Mark D. Minden, Vikas Gupta, Joseph Brandwein and Aaron D. Schimmer and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Andre C. Schuh

169 papers receiving 7.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1995 3.1k citations Andre C. Schuh et al. profile →
A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis

1997 726 citations Andre C. Schuh et al. profile →
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Hartmut Döhner, Keith W. Pratz et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Andre C. Schuh	4.9k	2.5k	1.4k	1.2k	1.0k	181	7.8k
Curt I. Civin	4.9k 1.0×	3.4k 1.4×	2.0k 1.4×	420 0.3×	1.1k 1.0×	202	9.3k
Bryan D. Young	5.2k 1.1×	1.9k 0.7×	1.6k 1.1×	359 0.3×	1.6k 1.5×	191	9.2k
Walter Fiedler	5.0k 1.0×	3.9k 1.6×	2.7k 2.0×	448 0.4×	1.2k 1.2×	299	9.5k
Ivan Maillard	3.7k 0.8×	1.2k 0.5×	1.5k 1.1×	478 0.4×	731 0.7×	152	8.1k
Yasuhide Hayashi	4.1k 0.8×	2.9k 1.2×	917 0.7×	281 0.2×	849 0.8×	226	7.1k
Justus Duyster	3.9k 0.8×	3.5k 1.4×	2.4k 1.8×	430 0.4×	1.2k 1.1×	261	9.0k
Shai Izraeli	2.6k 0.5×	1.7k 0.7×	885 0.7×	572 0.5×	972 0.9×	176	5.7k
Sérgio Dias	5.9k 1.2×	2.0k 0.8×	2.9k 2.2×	570 0.5×	2.4k 2.3×	86	9.7k
Hiromi Iwasaki	4.3k 0.9×	3.5k 1.4×	1.7k 1.3×	463 0.4×	586 0.6×	170	9.1k
Sakari Knuutila	3.8k 0.8×	1.4k 0.6×	1.7k 1.2×	353 0.3×	1.4k 1.4×	257	8.4k

Countries citing papers authored by Andre C. Schuh

Since Specialization

Citations

This map shows the geographic impact of Andre C. Schuh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andre C. Schuh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andre C. Schuh more than expected).

Fields of papers citing papers by Andre C. Schuh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andre C. Schuh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andre C. Schuh. The network helps show where Andre C. Schuh may publish in the future.

Co-authorship network of co-authors of Andre C. Schuh

This figure shows the co-authorship network connecting the top 25 collaborators of Andre C. Schuh. A scholar is included among the top collaborators of Andre C. Schuh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andre C. Schuh. Andre C. Schuh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richard‐Carpentier, Guillaume, Séverine Cathelin, Lisa Wang, et al.. (2025). Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial. The Lancet Haematology. 12(11). e887–e897.

Marks, David I., Ryan D. Cassaday, Josep‐María Ribera, et al.. (2025). Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review. Expert Review of Hematology. 18(1). 91–103. 1 indexed citations

D’Errico, Luigia, Mini Pakkal, Micheal McInnis, et al.. (2024). Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients. Journal of Clinical Medicine. 13(6). 1704–1704.

Davidson, Marta, James A. Kennedy, José‐Mario Capo‐Chichi, et al.. (2024). Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood Advances. 8(5). 1281–1294. 5 indexed citations

Davidson, Marta, Steven M. Chan, Hassan Sibai, et al.. (2024). FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience. Blood. 144(Supplement 1). 4273–4273.

Lucero, Josephine Anne, Igor Novitzky‐Basso, José‐Mario Capo‐Chichi, et al.. (2024). Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 103(4). 1187–1196. 3 indexed citations

Chen, Ruiqi, Eshetu G. Atenafu, Steven M. Chan, et al.. (2024). Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience. Leukemia Research. 147. 107586–107586.

Atenafu, Eshetu G., Steven M. Chan, Vikas Gupta, et al.. (2023). Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia. Acta Haematologica. 146(5). 366–372. 1 indexed citations

Döhner, Hartmut, Pau Montesinos, Ewa Zarzycka, et al.. (2023). P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE. HemaSphere. 7(S3). e83152da–e83152da.

10.

Menezes, Daniel L., Andrew H. Wei, Hartmut Döhner, et al.. (2023). P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL. HemaSphere. 7(S3). e930876b–e930876b. 1 indexed citations

11.

Tierens, Anne, Satoru Shinriki, Adam C. Smith, et al.. (2023). Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia. Frontiers in Oncology. 13. 1153082–1153082. 3 indexed citations

12.

Zhou, Qianghua, José‐Mario Capo‐Chichi, Andre C. Schuh, et al.. (2023). TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation. Cancers. 15(12). 3210–3210. 13 indexed citations

13.

Pollyea, Daniel A., Keith W. Pratz, Andrew H. Wei, et al.. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research. 28(24). 5272–5279. 75 indexed citations

14.

Atenafu, Eshetu G., Taylor Young, Steven M. Chan, et al.. (2022). Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen. SHILAP Revista de lepidopterología. 4(1). 232–235. 2 indexed citations

15.

Roboz, Gail J., Farhad Ravandi, Andrew H. Wei, et al.. (2022). Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 139(14). 2145–2155. 37 indexed citations

16.

Calvillo‐Argüelles, Oscar, Husam Abdel‐Qadir, Vikas Gupta, et al.. (2020). CLONAL HEMATOPOIESIS ASSOCIATED MUTATIONS, CARDIOVASCULAR EVENTS, AND ALL-CAUSE DEATH AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA. Journal of the American College of Cardiology. 75(11). 671–671.

17.

Munir, Talha, Andy C. Rawstron, Kristian Brock, et al.. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. British Journal of Haematology. 181. 34–35. 1 indexed citations

18.

Bhaskaran, Abhishek, L.G. Singer, Deepali Kumar, et al.. (2017). Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients. Clinical Microbiology and Infection. 24(6). 640–645. 18 indexed citations

19.

Shi, Yonghong, Jelena Tomić, David Cervi, et al.. (2004). Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells. Journal of Immunotherapy. 28(1). 28–39. 19 indexed citations

20.

Littlewood, Tim, et al.. (1998). Recombinant urate oxidase (SR 29142) to prevent hyperuricaemia during chemotherapy for haematological malignancies.. British Journal of Haematology. 101. 30–30. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact